CDK1 and cancer: According to published reports, acquired resistance to 1PTX in cancers involves other mechanisms, including altered drug efflux, epithelial–mesenchymal transition (EMT), microtubule dynamics, cyclin-dependent kinase 1 (CDK1), and cell death signaling12–14.